Internal Reference Number: FOI_6475
Date Request Received: 16/02/2022 00:00:00
Date Request Replied To: 09/03/2022 00:00:00
This response was sent via: By Email
Request Summary: Medication Information
Request Category: Private Individuals
Question Number 1: How many patients were treated by your Trust in the last 3 months with the following drugs: Adalimumab (Amgevita) Adalimumab (Humira) Adalimumab (Hyrimoz) Adalimumab (Idacio) Adalimumab (Imraldi) | |
Answer To Question 1: Amgevita 160 Humira 38 Hyrimoz 0 Idacio 0 Imraldi 140 | |
Question Number 2: Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible please provide new patients number by: New Humira patients – all departments New Humira patients – rheumatology New Humira patients – dermatology New Humira patients – gastroenterology | |
Answer To Question 2: All departments <5 Rheumatology 0 Dermatology 0 Gastroenterology <5 | |
Question Number 3: Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimioz, Idacio, Imraldi etc) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible provide new patients numbers by department: New Adalimumab Biosimilar patients – all departments New Adalimumab Biosimilar patients – rheumatology New Adalimumab Biosimilar patients – dermatology New Adalimumab Biosimilar patients – gastroenterology | |
Answer To Question 3: All departments 22 Rheumatology 18 Dermatology <5 Gastroenterology <5 | |
To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.